CUE Stock Summary and Trading Ideas (Cue Biopharma | NASDAQ:CUE)

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Cue Biopharma trades on the NASDAQ stock market under the symbol CUE.

As of September 22, 2026, CUE stock price climbed to $30.90 with 1,143,674 million shares trading.

CUE has a beta of 3.71, meaning it tends to be more sensitive to market movements. CUE has a correlation of 0.07 to the broad based SPY ETF.

CUE has a market cap of $224.47 million. This is considered a Small Cap stock.

Last quarter Cue Biopharma reported $8 million in Revenue and -$24.14 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$22.76.

In the last 3 years, CUE traded as high as $97.47 and as low as $4.97.

The top ETF exchange traded funds that CUE belongs to (by Net Assets): VTI, VXF, IWC, AVSC, DFAS.

CUE has outperformed the market in the last year with a price return of +53.3% while the SPY ETF gained +17.7%. CUE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.6% and +12.6%, respectively, while the SPY returned +3.8% and +0.7%, respectively.

CUE support price is $25.57 and resistance is $30.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUE shares will trade within this expected range on the day.